Mission
Cure CMD’s mission is to bring research, treatments and in the future, a cure for Congenital Muscular Dystrophies. Cure CMD will achieve this mission by working globally together with dedicated parent, government and research advocates. By focusing on this mission, Cure CMD will find and fund high potential research and clinical trials. Success will be determined by clinical applications that improve the lives of those afflicted with CMD’s.
Click here to download our brochure in English.
Click here to download our brochure in Italian.
Anne Rutkowski
Dr. Anne Rutkowski, Chairman
Dr. Anne Rutkowski, MD is Chairman of Cure CMD and a co-founder. Dr. Rutkowski is a practicing board certified emergency medicine physician in Los Angeles. Dr. Rutkowski’s daughter has congenital muscular dystrophy, subtype, dystroglycanopathy. Dr. Rutkowski graduated from the University of California Irvine Medical School, elected to Alpha Omega Alpha Honor Medical Society. She attended Bryn Mawr College as an undergraduate, graduating Magna cum laude with Honors in Biology. Prior to attending medical school, Dr. Rutkowski taught for 3 years in an inner city elementary school in Los Angeles, as part of Teach for America. She would like to shrink the diagnostic odyssey, see improvements and standardization of guidelines in medical care for all patients with CMD and a focused approach to identifying therapeutic targets. As a former educator, education and improved disease awareness are two further areas of focus for Cure CMD.
Patrick May
Patrick May, Treasurer/Secretary
Mr. Patrick May is the Chief Financial Officer of Cure CMD and a co-founder. Mr. May is a Certified Public Accountant with eight years of experience as a Controller/Treasurer for a for-profit corporation in the greater Kansas City area. Previously he gained four years experience as an auditor with a Big 4 international accounting firm. He graduated Magna Cum Laude from the University of Notre Dame. Patrick is the father of a daughter diagnosed with merosin deficient congenital muscular dystrophy. He shares the vision for CMD to promote awareness and ultimately accelerate therapies and a cure for congenital muscular dystrophy.
We would like to acknowledge Richard Cloud’s outstanding contribution to Cure CMD as one of the original co-founders and former Chairman. Richard Cloud is currently CEO of Prothelia, Inc, a biotech company focused exclusively on muscular dystrophy therapies.
Contact
Cure CMD
P.O. Box 701
Olathe, KS 66051
Ph. 1-866-400-3626
RareShare
RareShare is dedicated to building international online communities designed to increase the level of communication and support among patients, families and healthcare professionals affected by rare disorders.
